Total raised
—
Last: Undisclosed 2015-05
Stage
Acquired
Founded
2011
Headcount
6
HQ
Pardes Hanna-Karkur
Sector
Health Tech & Life Sciences
About
Nitiloop has developed the NovaCross, a microcatheter that enables guidewire positioning and distal support, with an extendable segment for additional support. The NovaCross, comprising a competent supporting microcatheter and a low-profile microcatheter, uses an operator-controlled nitinol scaffold and an extendable segment, both at its distal tip. The proprietary platform used in the NovaCross is also used as a basis for additional products intended for below-the-knee and embolotherapy applications, the treatment of liver cancer with chemotherapy, and the injection of radiation beads through the microcatheter.
Funding history · 1 round · — total
2015-05
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary product developed by NitiLoop?
- NitiLoop has developed the NovaCross, a microcatheter designed to enable guidewire positioning and distal support, featuring an extendable segment for additional support.
- When was NitiLoop founded and where is its headquarters located?
- NitiLoop was founded in January 2011 and is headquartered in Pardes Hanna-Karkur, Israel.
- What is the current status of NitiLoop?
- NitiLoop is currently inactive, having been acquired by Microbot Medical in October 2022.
- Which company acquired NitiLoop and when did this acquisition occur?
- NitiLoop was acquired by Microbot Medical in October 2022.
- When did NitiLoop receive FDA 510(k) Clearance for its NovaCross Microcatheter?
- NitiLoop announced FDA 510(k) Clearance for its NovaCross Microcatheter in May 2015, for supporting guidewire access to discrete regions of the coronary and peripheral vasculature.
- What additional FDA clearances did NitiLoop receive in October 2017?
- In October 2017, NitiLoop announced FDA 510(k) Clearance for its Nova Cross Extreme and Nova Cross BTK Micro catheter, intended for guidewire access support in coronary and peripheral vasculature.
- What significant regulatory achievement did NitiLoop's NovaCross achieve in April 2020?
- In April 2020, NitiLoop's NovaCross earned FDA Clearance for treating Chronic Total Occlusion (CTO) prior to PTCA or stent intervention.
- Which investors participated in NitiLoop's undisclosed funding round in May 2015?
- In May 2015, NitiLoop secured an undisclosed funding round with lead investor Accelmed, also including Access Medical Ventures.
- How many employees does NitiLoop have?
- NitiLoop has 6 employees.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B
Tags
medical-devicescathetershospitalscardiovascularcardiologysurgerysurgeons